Na faalauiloa e Boehringer Ingelheim i aso nei e faapea o le US Food and Drug Administration (FDA) na tuuina atu le Breakthrough Therapy Designation i lana tala fou suʻesuʻega togafitiga, BI 1015550, mo le togafitia o le idiopathic pulmonary fibrosis (IPF). O le BI 1015550 ose fa'agata fa'agutu, phosphodiesterase 4B (PDE4B) e mafai ona foia uma le pulmonary fibrosis - o se ma'ila e le mafai ona toe fa'afo'isia o le tino e afaina ai le tino - ma le mumū e feso'ota'i ma fa'ama'i o le mama interstitial fibrosing alualu i luma (ILDs).
"O le faʻavaveina o le atinaʻeina o le BI 1015550 o se vaega o le isi galu a Boehringer Ingelheim o togafitiga fou faʻapitoa mo faʻamaʻi faʻamaʻi vavalalata e faʻatatau i le faʻasaoina o le mama ma faʻaleleia olaga o tagata mamaʻi," o le tala lea a Thomas Seck, MD, sui peresitene sinia, Medicine and Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "BI 1015550 o loʻo faʻatusalia le mole muamua i le vasega o PDE4B inhibitors o loʻo suʻesuʻeina mo le IPF ma isi ILDs fibrosing alualu i luma. Ua matou fausia i luga o la matou measina i le pulmonary fibrosis ma o loʻo galulue i luga o le faʻailoga mataʻutia ma faʻamaumauga faʻapitoa ma le faʻamoemoe o lenei vailaʻau fou e mafai ona oʻo atu i tagata mamaʻi i se taimi vave."
